• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Amrix (cyclobenzaprine hydrochloride extended release)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Amrix (cyclobenzaprine hydrochloride extended release)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Amrix (cyclobenzaprine hydrochloride) is a once daily extended release skeletal muscle relaxant which relieves muscle spasm of local origin without interfering with muscle function. The exact mechanism of action is unknown. However, cyclobenzaprine hydrochloride is thought to act primarily at brain stem (and to a lesser extent at spinal cord level) to relieve skeletal muscle spasms of local origin without altering muscle function.

    Amris is specifically indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

    Amrix is supplied as 15mg and 30mg capsules for oral administration. The recommended initial dose of the drug is one (1) 15 mg capsule taken once daily. Some patients may require up to 30 mg/day, given as one (1) 30 mg capsule taken once daily or as two (2) 15 mg capsules taken once daily. It is recommended that doses be taken at approximately the same time each day. Use of Amrix for periods longer than two or three weeks is not recommended.

    Clinical Results

    FDA Approval
    The FDA approval of Amrix was based on the results of two identical double-blind, parallel-group, placebo-controlled studies: Study 1105 evaluated 30 mg of Amrix and Study 1106 studied 15 mg of Amrix both taken once daily for 14 days. The primary efficacy endpoint was the patient’s rating of medication helpfulness, measured at Day 4 and Day 14, between the two Amrix arms versus placebo. The primary endpoint was reached with signifcance for both Amrix arms. In addition, one of the two studies demonstrated significant differences between the Amrix 30 mg group and the placebo group in terms of patient-rated relief from local pain due to muscle spasm at Day 4 and Day 8, in subject-rated restriction of movement at Day 4 and Day 8, and in patient-rated global impression of change at Day 4, Day 8, and Day 14.

    Side Effects

    Adverse events associated with the use of Amrix may include, but are not limited to, the following:

    • Dry mouth
    • Dizziness
    • Fatigue
    • Somnolence
    • Headache
    • Nausea

    Mechanism of Action

    Amrix (cyclobenzaprine hydrochloride) is a once daily extended release skeletal muscle relaxant which relieves muscle spasm of local origin without interfering with muscle function. The exact mechanism of action is unknown. However, cyclobenzaprine hydrochloride is thought to act primarily at brain stem (and to a lesser extent at spinal cord level) to relieve skeletal muscle spasms of local origin without altering muscle function.

    Literature References

    Malanga GA, Ruoff GE, Weil AJ, Altman CA, Xie F, Borenstein DG Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: two randomized, double-blind, placebo-controlled studies of identical design. Current Medical Research and Opinion< 2009 May;25(5):1179-96

    Darwish M, Hellriegel ET, Xie F Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study. Clinical Drug Investigation 2008;28(12):793-801

    Additional Information

    For additional information regarding Amrix or muscle spasms, please visit the Amrix web page.
    Approval Date: 2007-02-01
    Company Name: Cephalon
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing